Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Copper
Therapeutic Area : Dermatology
Study Phase : Phase II/ Phase III
Recipient : Hospital Israelita Albert Einstein
Deal Size : Inapplicable
Deal Type : Inapplicable
COPPER: A Trial Evaluating Copper-based Products for Incontinence-associated Dermatitis
Details : Copper is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Dermatitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 10, 2024
Lead Product(s) : Copper
Therapeutic Area : Dermatology
Highest Development Status : Phase II/ Phase III
Recipient : Hospital Israelita Albert Einstein
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dialkylcarbamoylchloride
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Approved FDF
Recipient : Abigo Medical AB
Deal Size : Undisclosed
Deal Type : Acquisition
Essity Acquires 75% of the Medical Solutions Company ABIGO Medical AB
Details : ABIGO Medical has leading innovations in advanced wound care that reduce the spread of bacteria without increasing resistance to antibiotics.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
February 27, 2020
Lead Product(s) : Dialkylcarbamoylchloride
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Approved FDF
Recipient : Abigo Medical AB
Deal Size : Undisclosed
Deal Type : Acquisition